KR960021026A - 세파클로르의 약제학적 제제 - Google Patents
세파클로르의 약제학적 제제 Download PDFInfo
- Publication number
- KR960021026A KR960021026A KR1019950024359A KR19950024359A KR960021026A KR 960021026 A KR960021026 A KR 960021026A KR 1019950024359 A KR1019950024359 A KR 1019950024359A KR 19950024359 A KR19950024359 A KR 19950024359A KR 960021026 A KR960021026 A KR 960021026A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- weight
- total weight
- amount
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
본 발명은 제제 총 중량을 기준하여 35중량% 내지 50중량%의 양의 항생제 세파클로로를, 붕해제, 희석제, 윤활제, 부착방지제, 감미제, 향 및 임의로 향미제, 유백제 및 착색제와 함께 함유하는, 직접 압착에 의한 분산성 정제의 제조에 적합한 세파클로로의 약제학적 제제에 관한 것이다. 당해 제제는 19 내지 21℃의 수중에서 3분 미만내에 붕해되는 분산성 정제의 제조에 적합하고 세파클로르에 민감한 박테리아 균주에 의해 유발된 감염 치료에 적합하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (24)
- 활성성분으로서의 제제 총 중량을 기준하여 35중량% 내지 50중량%의 양의 세파클로르를 적합한 부형제 및 보조부가제와 함께 포함하는, 직접 압착에 의한 분산성 정제의 제조에 적합한 약제학적 제제.
- 제1항에 있어서, 적합한 부형제 및 보조부가제가 붕해제, 희석제, 윤활제, 부착방지제, 감미제, 향 및 임의로 향미제, 유백제 및 착색제를 포함하는 제제.
- 제2항에 있어서, 붕해제가 글리콜레이트 나트륨 전분, 아크릴산 유도체, 글리콜레이트 나트륨 전분과 카복시메틸셀룰로즈의 혼합물, 및 바람직하게는 크로스포비돈인 제제.
- 제3항에 있어서, 제제 총 중량을 기준하여 5 내지 21중량%의 양의 글리콜레이트 나트륨 전분을 포함하는 제제.
- 제3항에 있어서, 제제 총 중량을 기준하여 약10중량%의 양의 아크릴산 유도체를 포함하는 제제.
- 제3항에 있어서, 제제 총 중량을 기준하여 약10중량%의 양의 크로스포비돈을 포함하는 제제.
- 제3항에 있어서, (ⅰ)제제 총 중량을 기준하여 약14중량%의 양의 글리콜레이트 나트륨 전분과 (ⅱ)제제 총 중량을 기준하여 약10중량%의 양의 카복시메틸셀룰로즈의 혼합물을 붕해제로서 포함하는 제제.
- 제2항에 있어서, 희석제로서, 미세결정성 셀룰로즈, 무수유등 전문 및 이들의 혼합물을 포함하는 제제.
- 제8항에 있어서, 제제 총 중량을 기준하여 약24중량% 내지 46중량%의 양의 미세결정성 셀룰로즈를 포함하는 제제.
- 제9항에 있어서, 미세결정성 셀룰로즈의 평균 입자 크기가 약 90 μ인 제제.
- 제8항에 있어서, 제제 총 중량을 기준하여 약39중량%의 양의 무수 유동 전분을 포함하는 제제.
- 제2항에 있어서 제제 총 중량을 기준하여 2중량% 미만의 양의 스테아릴 나트륨 푸마레이트를 윤활제로서 포함하는 제제.
- 제2항에 있어서 제제 총 중량을 기준하여 5중량% 미만의 양의 콜로이드성 이산화규소를 부착방지제로서 포함하는 제제.
- 제2항에 있어서 제제 총 중량을 기준하여 1중량% 미만의 양의 아스파프탐, 나트륨 사카린 또는 이들의 혼합물을 감미제로서 포함하는 제제.
- 제14항에 있어서, 제제 총 중량을 기준하여 0.1중량% 내지 0.4중량%의 양의 나트륨 사카린을 포함하는 제제.
- 제14항에 있어서, 제제 총 중량을 기준하여 0.2중량% 내지 0.7중량%의 양의 아스파르탐을 포함하는 제제.
- 제2항에 있어서, 제제 총 중량을 기준하여 3중량% 내지 5중량%의 양의 딸기향을 포함하는 제제.
- 제2항에 있어서, 제제 총 중량을 기준하여 2중량% 내지 4중량%의 양의 무수 시트르산을 향미제로서 포함하는 제제.
- 제2항에 있어서, 제제 총 중량을 기준하여 2중량% 미만의 양의 이산화티탄을 유백제로서 포함하는 제제.
- 제2항에 있어서, 제제 총 중량을 기준하여 1중량% 미만의 양의 레드 F, D 및 C 제3호-에리트로신을 착색제로서 포함하는 제제.
- 제1항에 있어서, 비등 효과를 나타내는 한 쌍의 화합물을 포함하는 제제.
- 제21항에 있어서, 한 쌍의 비등제가 시트르산과 탄산칼슘으로 구성되는 제제.
- 제1항 내지 제22항 중의 어느 한 항에 따른 약제학적 제제를 직접 압착시켜 수득될 수 있는 분산성 세파클로르 정제.
- 제1항 내지 제22항중의 어느 한 항에 따르는 약제학적 제제를 직접 압착시킴을 포함하는, 세파클로르함유 분산성 정제의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES09402530A ES2079327B1 (es) | 1994-12-13 | 1994-12-13 | Formulaciones farmaceuticas de cefaclor. |
| ES9402530 | 1994-12-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960021026A true KR960021026A (ko) | 1996-07-18 |
| KR100350565B1 KR100350565B1 (ko) | 2003-02-05 |
Family
ID=8288235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950024359A KR100350565B1 (ko) | 1994-12-13 | 1995-08-08 | 세파클로르의약제학적제제 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5861141A (ko) |
| EP (3) | EP0716852B1 (ko) |
| JP (1) | JPH08208484A (ko) |
| KR (1) | KR100350565B1 (ko) |
| CN (1) | CN1136852C (ko) |
| AT (1) | ATE201984T1 (ko) |
| AU (1) | AU702585B2 (ko) |
| BR (1) | BR9504573A (ko) |
| CA (1) | CA2158511A1 (ko) |
| CO (1) | CO4410176A1 (ko) |
| CZ (1) | CZ287248B6 (ko) |
| DE (2) | DE69521275T2 (ko) |
| DK (1) | DK0716852T3 (ko) |
| ES (2) | ES2079327B1 (ko) |
| FI (1) | FI953887A (ko) |
| GR (2) | GR960300062T1 (ko) |
| HK (1) | HK1012574A1 (ko) |
| HU (1) | HUT73792A (ko) |
| IL (1) | IL114642A (ko) |
| MY (1) | MY114687A (ko) |
| NO (1) | NO309925B1 (ko) |
| NZ (1) | NZ272611A (ko) |
| PE (1) | PE5196A1 (ko) |
| PL (1) | PL181437B1 (ko) |
| PT (1) | PT716852E (ko) |
| RU (1) | RU2150276C1 (ko) |
| SI (1) | SI0716852T1 (ko) |
| TR (1) | TR199501165A1 (ko) |
| TW (1) | TW492875B (ko) |
| UA (1) | UA34479C2 (ko) |
| YU (1) | YU60795A (ko) |
| ZA (1) | ZA956411B (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69712332T2 (de) * | 1996-02-29 | 2002-10-02 | Fujisawa Pharmaceutical Co | Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung |
| AU1150799A (en) * | 1997-10-10 | 1999-05-03 | Yamanouchi Europe B.V. | Oral compositions containing a cephalosporin antibiotic |
| BR9915835A (pt) * | 1998-12-01 | 2001-08-21 | Novo Nordisk As | Composição farmacêutica, e, processo para a preparação de uma composição |
| DE10005017A1 (de) * | 2000-02-04 | 2001-08-09 | Cognis Deutschland Gmbh | Duftstofftabletten |
| AU2002236166B2 (en) * | 2001-05-01 | 2006-12-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition |
| US7151432B2 (en) | 2001-09-19 | 2006-12-19 | Immersion Corporation | Circuit and method for a switch matrix and switch sensing |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| TW200404550A (en) * | 2002-07-08 | 2004-04-01 | Sankyo Co | Cepharospolin formulation for oral use |
| JP4526247B2 (ja) * | 2002-07-08 | 2010-08-18 | 第一三共株式会社 | 経口用セファロスポリン製剤 |
| DK1732605T3 (da) | 2004-03-29 | 2019-06-11 | Wyeth Llc | Multi-vitamin- og mineral-kosttilskud |
| US8968768B2 (en) * | 2004-03-29 | 2015-03-03 | Wyeth Llc | Phytosterol nutritional supplements |
| EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| KR101465803B1 (ko) | 2005-08-10 | 2014-11-26 | 시오노기세이야쿠가부시키가이샤 | 구강내 붕괴 정제 |
| CN102579455B (zh) * | 2012-03-19 | 2014-02-19 | 迪沙药业集团有限公司 | 一种稳定的头孢克洛咀嚼组合物 |
| JP6841819B2 (ja) * | 2015-09-14 | 2021-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 制御され、遅延された活性成分の放出を有する製剤 |
| CN113750066B (zh) * | 2021-10-12 | 2022-12-02 | 上海金城素智药业有限公司 | 一种具有临床优势的头孢克洛制剂及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2259646C2 (de) * | 1972-12-06 | 1984-11-22 | Hoechst Ag, 6230 Frankfurt | Hochdosierte Tabletten von Cephalosporin-Derivaten sowie Verfahren zu ihrer Herstellung |
| US3925372A (en) | 1973-02-23 | 1975-12-09 | Lilly Co Eli | Alpha-aminoacyl-3-halo cephalosporins |
| YU36970B (en) | 1973-02-23 | 1984-08-31 | Lilly Co Eli | Process for obtaining 7-(amino)-acylamido-3-halocephalosporins |
| US4143129A (en) * | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
| GB2066662B (en) * | 1979-12-21 | 1984-02-15 | Glaxo Group Ltd | Cephalexin powder compositions containing silicon dioxide |
| NZ198241A (en) * | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| JPS601128A (ja) * | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | 作用持続型セフアクロル製剤 |
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| DE3887179T2 (de) * | 1987-03-02 | 1994-06-16 | Brocades Pharma Bv | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. |
| DE3868245D1 (de) * | 1987-11-30 | 1992-03-12 | Gist Brocades Nv | Pharmazeutische zusammensetzung und verfahren zu ihrer herstellung. |
| DE3838431A1 (de) * | 1988-11-12 | 1990-05-17 | Bayer Ag | Ibuprofen-brausezubereitungen |
| GB9009473D0 (en) * | 1990-04-27 | 1990-06-20 | Beecham Group Plc | Pharmaceutical formulation |
| FR2669221B1 (fr) * | 1990-11-15 | 1993-01-15 | Rhone Poulenc Sante | Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique. |
| EP0487774B1 (en) * | 1990-11-29 | 1994-10-26 | Wei Ming Pharmaceutical Mfg. Co. Ltd. | A direct tabletting auxiliary |
| MY110880A (en) * | 1991-01-30 | 1999-06-30 | The Wellcome Foundation Ltd | Water-dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| IT1251999B (it) * | 1991-11-11 | 1995-05-27 | Opos Biochimica Srl | Forma cristallina di un antibiotico cefalosporinico |
| AU674516B2 (en) * | 1992-04-30 | 1997-01-02 | Schering Corporation | Stable hydrated cephalosporin dry powder for oral suspension formulation |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5616344A (en) * | 1994-06-14 | 1997-04-01 | Fuisz Technologies Ltd. | Apparatus and process for strengthening low density compression dosage units and product therefrom |
| US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
| US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
-
1994
- 1994-12-13 ES ES09402530A patent/ES2079327B1/es not_active Expired - Lifetime
-
1995
- 1995-07-17 PT PT95304976T patent/PT716852E/pt unknown
- 1995-07-17 EP EP95304976A patent/EP0716852B1/en not_active Expired - Lifetime
- 1995-07-17 DE DE69521275T patent/DE69521275T2/de not_active Expired - Fee Related
- 1995-07-17 ES ES95304976T patent/ES2091738T3/es not_active Expired - Lifetime
- 1995-07-17 DE DE0716852T patent/DE716852T1/de active Pending
- 1995-07-17 AT AT95304976T patent/ATE201984T1/de not_active IP Right Cessation
- 1995-07-17 SI SI9530516T patent/SI0716852T1/xx unknown
- 1995-07-17 EP EP00126491A patent/EP1086690A3/en not_active Withdrawn
- 1995-07-17 DK DK95304976T patent/DK0716852T3/da active
- 1995-07-17 EP EP00126490A patent/EP1086689A3/en not_active Withdrawn
- 1995-07-18 PE PE1995274137A patent/PE5196A1/es not_active Application Discontinuation
- 1995-07-18 IL IL11464295A patent/IL114642A/xx not_active IP Right Cessation
- 1995-07-18 HU HU9502160A patent/HUT73792A/hu unknown
- 1995-07-19 CO CO95032103A patent/CO4410176A1/es unknown
- 1995-07-19 NZ NZ272611A patent/NZ272611A/xx unknown
- 1995-07-20 AU AU25094/95A patent/AU702585B2/en not_active Ceased
- 1995-08-01 ZA ZA956411A patent/ZA956411B/xx unknown
- 1995-08-02 PL PL95309863A patent/PL181437B1/pl not_active IP Right Cessation
- 1995-08-03 CZ CZ19951998A patent/CZ287248B6/cs not_active IP Right Cessation
- 1995-08-08 KR KR1019950024359A patent/KR100350565B1/ko not_active IP Right Cessation
- 1995-08-14 NO NO953192A patent/NO309925B1/no unknown
- 1995-08-17 FI FI953887A patent/FI953887A/fi not_active IP Right Cessation
- 1995-08-18 RU RU95113968/14A patent/RU2150276C1/ru not_active IP Right Cessation
- 1995-09-02 TW TW084109243A patent/TW492875B/zh not_active IP Right Cessation
- 1995-09-18 CA CA002158511A patent/CA2158511A1/en not_active Abandoned
- 1995-09-18 YU YU60795A patent/YU60795A/sh unknown
- 1995-09-25 TR TR95/01165A patent/TR199501165A1/xx unknown
- 1995-10-13 US US08/542,853 patent/US5861141A/en not_active Expired - Fee Related
- 1995-10-26 BR BR9504573A patent/BR9504573A/pt not_active IP Right Cessation
- 1995-11-17 MY MYPI95003503A patent/MY114687A/en unknown
- 1995-12-12 UA UA95125252A patent/UA34479C2/uk unknown
- 1995-12-12 JP JP7322647A patent/JPH08208484A/ja active Pending
- 1995-12-13 CN CNB951213199A patent/CN1136852C/zh not_active Expired - Fee Related
-
1996
- 1996-11-30 GR GR960300062T patent/GR960300062T1/el unknown
-
1998
- 1998-12-17 HK HK98113978A patent/HK1012574A1/xx not_active IP Right Cessation
-
2001
- 2001-08-31 GR GR20010401363T patent/GR3036503T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960021026A (ko) | 세파클로르의 약제학적 제제 | |
| KR960003720A (ko) | 플루옥세틴 약제학적 제형 | |
| TR200001542T2 (tr) | Mide fundusunu gevşetici özelliklere sahip (benzodioksan, benzofuran veya benzopiran) türevleri. | |
| DE68902531D1 (de) | Dispergierbare zubereitung. | |
| RU95113968A (ru) | Фармацевтические препаративные формы цефаклора и способ их получения | |
| RU93052161A (ru) | Лекарственные средства, содержащие производные имидазол-1-ила |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 13 |
|
| EXPY | Expiration of term |